TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY

过继免疫治疗中 NK 细胞的肿瘤定位/治疗活性

基本信息

  • 批准号:
    6323292
  • 负责人:
  • 金额:
    $ 17.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-07-01 至 2002-06-30
  • 项目状态:
    已结题

项目摘要

Very little is known about the basis for the success or failure of adoptive-immunotherapy (AIT), but with increased insight into the anti-tumor mechanism(s) of adoptively transferred effector cells, it may be possible to improve considerably this therapeutic modality. Thus, with the objective of evaluating and improving the efficacy of IL-2-activated NK cells as effector cells in AIT of cancer, the ability of these cells to localize into tumors following adoptive transfer will be investigated, and their anti-tumor effect in vivo against established metastases will be analyzed. Based on previous work in syngeneic rodent models of lung and liver metastases, it is hypothesized that while a certain number of A- NK cells must probably localize into the malignant tissue in order to induce its regression, the number might differ depending on the location of the metastases and on their histological type. Furthermore, while localization of A-NK cells in the malignant tissues appears to be a prerequisite for therapeutic effect, it might not along guarantee therapeutic efficacy. It is predicted that the success of A-NK cells in AIT will depend on both the delivery of sufficient numbers of effector cells specifically to the malignant tissue, and the maintenance of the anti-tumor activity of the injected effector cells. To test this prediction and the associated hypotheses, the following will be examined: a) the ability of A- NK cells to localize into rodent experimental metastases in lungs, livers, peritoneal cavity, and subcutaneous tissue; b) The relationship in various organs between the density of tumor- infiltrating A-NK cells and therapeutic efficacy; c) The influence of tumor heterogeneity and vascularization on the ability of A-NK cells to localize at sites of tumors; d) The functional status of tumor-infiltrating A-NK cells and f) the possible presence of factors in the tumor milieu which might downregulate or damage the A-NK cells, and e) Strategies for counteracting the inhibitory effect of intratumoral suppressor factors, and the possibility to obtain high intratumoral concentrations of IL-2 by the use of long- lived Peg-IL-2 instead of short-lived regular IL-2. The results of there investigations should help to identify the optimal conditions for A-NK cell-based AIT of cancer and provide indications of the key parameters to consider and assess in analogous trials of clinical AIT for patients with metastatic cancer.
的成功或失败的基础所知甚少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Per H. Basse其他文献

270. The RheoSwitch® Therapeutic System Precisely Regulates IL-2 Expression in Melanoma Cells and Supports Survival of NK Cells at the Tumor Site
  • DOI:
    10.1016/j.ymthe.2006.08.324
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Anand K. Katakam;Qin Yang;Steve Goding;Prasanna Kumar;Per H. Basse
  • 通讯作者:
    Per H. Basse

Per H. Basse的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Per H. Basse', 18)}}的其他基金

Augmentation of NK cell-mediated anti-cancer activity by dietary BITC
通过膳食 BITC 增强 NK 细胞介导的抗癌活性
  • 批准号:
    7701342
  • 财政年份:
    2009
  • 资助金额:
    $ 17.92万
  • 项目类别:
INITIATING THE ADAPTIVE IMMUNE RESPONSE TO CANCER
启动对癌症的适应性免疫反应
  • 批准号:
    7128908
  • 财政年份:
    2005
  • 资助金额:
    $ 17.92万
  • 项目类别:
Cytokine Delivery By Tumor-Seeking Lymphocytes
肿瘤寻找淋巴细胞的细胞因子传递
  • 批准号:
    6865438
  • 财政年份:
    2004
  • 资助金额:
    $ 17.92万
  • 项目类别:
Cytokine Delivery By Tumor-Seeking Lymphocytes
肿瘤寻找淋巴细胞的细胞因子传递
  • 批准号:
    6709079
  • 财政年份:
    2004
  • 资助金额:
    $ 17.92万
  • 项目类别:
Cytokine Delivery By Tumor-Seeking Lymphocytes
肿瘤寻找淋巴细胞的细胞因子传递
  • 批准号:
    7010096
  • 财政年份:
    2004
  • 资助金额:
    $ 17.92万
  • 项目类别:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
癌症靶向化学免疫治疗的新策略
  • 批准号:
    6621281
  • 财政年份:
    2002
  • 资助金额:
    $ 17.92万
  • 项目类别:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
癌症靶向化学免疫治疗的新策略
  • 批准号:
    6431298
  • 财政年份:
    2002
  • 资助金额:
    $ 17.92万
  • 项目类别:
A New Strategy for Targeted Chemoimmunotherapy of Cancer
癌症靶向化学免疫治疗的新策略
  • 批准号:
    6687272
  • 财政年份:
    2002
  • 资助金额:
    $ 17.92万
  • 项目类别:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
过继免疫治疗中 NK 细胞的肿瘤定位/治疗活性
  • 批准号:
    6203349
  • 财政年份:
    1999
  • 资助金额:
    $ 17.92万
  • 项目类别:
TUMOR LOCALIZATION/THERAPEUTIC ACTIVITY OF NK CELLS IN ADOPTIVE IMMUNOTHERAPY
过继免疫治疗中 NK 细胞的肿瘤定位/治疗活性
  • 批准号:
    6103168
  • 财政年份:
    1998
  • 资助金额:
    $ 17.92万
  • 项目类别:

相似海外基金

Development of platform for non-invasive, rapid, and simple analysis of cytokine secretion from single cells
开发非侵入、快速、简单分析单细胞细胞因子分泌的平台
  • 批准号:
    23H01824
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic approach to confer an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine in effector T cells
赋予效应T细胞中促肿瘤细胞因子IL-6抗肿瘤作用的治疗方法
  • 批准号:
    23K06723
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Diversity of haematopoietic cytokine receptor activation exploring with marine probes
用海洋探针探索造血细胞因子受体激活的多样性
  • 批准号:
    23K14019
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
FOXA1 通过 ARID1A 调节前列腺癌中的细胞因子信号传导和免疫景观
  • 批准号:
    10681898
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
Cytokine Regulation of Secondary Neural Progenitors
次级神经祖细胞的细胞因子调节
  • 批准号:
    10752901
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
A point-of-care salivary cytokine test for early detection of oral cancer
用于早期发现口腔癌的即时唾液细胞因子检测
  • 批准号:
    10760626
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
Development of Coccidioides Cytokine Release Assay
球孢子菌细胞因子释放测定的发展
  • 批准号:
    10760131
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
Generating a novel conditional knockout mouse for a super-enhancer that controls cytokine responsiveness
生成一种新型条件敲除小鼠,用于控制细胞因子反应的超级增强子
  • 批准号:
    10740932
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
Cytokine receptor common beta chain alterations in mediastinal lymphomas
纵隔淋巴瘤细胞因子受体常见β链改变
  • 批准号:
    489197
  • 财政年份:
    2023
  • 资助金额:
    $ 17.92万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了